Interventions to reduce progression of CKD what is the evidence? John Feehally
|
|
|
- Archibald Woods
- 5 years ago
- Views:
Transcription
1 Interventions to reduce progression of CKD what is the evidence? John Feehally
2 Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think we know Disappointing that we are still debating long-established therapies Disappointing that mechanistic studies have been slow to yield new targeted therapy Designing high quality trials
3 Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think we know Disappointing that we are still debating long-established therapies Disappointing that mechanistic studies have been slow to yield new targeted therapy Designing high quality trials
4 Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think we know Disappointing that we are still debating long-established therapies Disappointing that mechanistic studies have been slow to yield new targeted therapy Designing high quality trials
5 Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think we know Disappointing that we are still debating long-established therapies Disappointing that mechanistic studies have been slow to yield new targeted therapy Designing high quality trials
6 Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think we know Disappointing that we are still debating long-established therapies Disappointing that mechanistic studies have been slow to yield new targeted therapy Designing high quality trials
7 Interventions to reduce progression of CKD what is the evidence? CHALLENGES IN DESIGNING CLINICAL TRIALS Definitive end-points (e.g. preventing ESRD) need long trials Acceptable surrogate end-points Identify those at low risk of progression
8
9 Interventions to reduce progression of CKD what is the evidence? CHALLENGES IN DESIGNING CLINICAL TRIALS Definitive end-points (e.g. preventing ESRD) need long trials Acceptable surrogate end-points Identify those at low risk of progression Trials versus real life office, home, or ambulatory BP monitoring? albuminuria or proteinuria? spot or timed urine collections?
10 Interventions to reduce progression of CKD what is the evidence? Quality of Evidence GOOD MODERATE INSUFFICIENT Evidence of HARM BP control RAS blockade Uric acid lowering Alkali Physical exercise Dietary protein restriction Smoking cessation Salt restriction Anemia correction Statins Weight loss High fluid intake Bardoxolone
11 Interventions to reduce progression of CKD what is the evidence? Quality of Evidence GOOD MODERATE INSUFFICIENT Evidence of HARM BP control RAS blockade Uric acid lowering Alkali Physical exercise Dietary protein restriction Smoking cessation Salt restriction Anemia correction Statins Weight loss High fluid intake Bardoxolone
12 Interventions to reduce progression INTERVENTIONS WITH EVIDENCE OF HARM BARDOXOLONE An oral anti-oxidant inflammation modulator NrF2 activator
13 Interventions to reduce progression INTERVENTIONS WITH EVIDENCE OF HARM BEAM Phase 2, double-blind RCT Type 2 diabetes n = 227 Stage 3b-4 CKD egfr increased up to 52 weeks Minor adverse effects Pergola PE et al. NEJM 2011;365:327 BARDOXOLONE An oral anti-oxidant inflammation modulator NrF2 activator
14 Interventions to reduce progression INTERVENTIONS WITH EVIDENCE OF HARM BARDOXOLONE An oral anti-oxidant inflammation modulator NrF2 activator BEAM Phase 2, double-blind RCT Type 2 diabetes n = 227 Stage 3b-4 CKD egfr increased up to 52 weeks Minor adverse effects Pergola PE et al. NEJM 2011;365:327 BEACON Double blind RCT Type 2 diabetes n=2185 Stage 4 CKD Study terminated at 9 months Excess mortality Excess hospitalisation for heart failure de Zeeuw D et al. NEJM 2013;369:2492
15 Interventions to reduce progression of CKD what is the evidence? Quality of Evidence GOOD MODERATE INSUFFICIENT Evidence of HARM BP control RAS blockade Uric acid lowering Alkali Physical exercise Dietary protein restriction Smoking cessation Salt restriction Anemia correction Statins Weight loss High fluid intake Bardoxolone
16 Interventions to reduce progression INTERVENTIONS WITH INSUFFICIENT EVIDENCE OF BENEFIT Correction of anaemia Statins Weight loss High fluid intake
17 Interventions to reduce progression INTERVENTIONS WITH INSUFFICIENT EVIDENCE OF BENEFIT Correction of anaemia Statins Weight loss High fluid intake
18 Interventions to reduce progression INTERVENTIONS WITH INSUFFICIENT EVIDENCE OF BENEFIT WEIGHT LOSS Morbid obesity & segmental sclerosis
19 Interventions to reduce progression INTERVENTIONS WITH INSUFFICIENT EVIDENCE OF BENEFIT WEIGHT LOSS Morbid obesity & segmental sclerosis Moderate obesity with CKD: weight loss reduces proteinuria
20 Interventions to reduce progression INTERVENTIONS WITH INSUFFICIENT EVIDENCE OF BENEFIT WEIGHT LOSS Morbid obesity & segmental sclerosis Moderate obesity with CKD: weight loss reduces proteinuria What is the ideal body weight?
21 Association of BMI with Outcomes in CKD 453,596 US veterans - egfr < 60, mean age 73yrs, 87% White MORTALITY Lu JL et al. JASN 2014; 25: 2088
22 Association of BMI with Outcomes in CKD 453,596 US veterans - egfr < 60, mean age 73yrs, 87% White MORTALITY <25 >35 Lu JL et al. JASN 2014; 25: 2088
23 Interventions to reduce progression INTERVENTIONS WITH INSUFFICIENT EVIDENCE OF BENEFIT What is the ideal body weight in CKD? 453,596 US veterans, egfr < 60 - mean age 73 yrs - 87% White U-shaped curve Worst renal outcomes: BMI < 25 & BMI > 35 Best outcomes: BMI Lu JL et al. JASN 2014 Epub Mar 20
24 Interventions to reduce progression INTERVENTIONS WITH INSUFFICIENT EVIDENCE OF BENEFIT Correction of anaemia Statins Weight loss High fluid intake
25 Is there a right amount of fluid to drink if you have CKD? Drinking eight glasses of water each day (~ 2.5L) is widely believed to improve kidney health in the USA 8 by 8
26 Is there a right amount of fluid to drink if you have CKD? Drinking eight glasses of water each day (~ 2.5L) in the USA 8 by 8 is widely believed to improve kidney health Three cross-sectional epidemiological studies
27 Is there a right amount of fluid to drink if you have CKD? Drinking eight glasses of water each day (~ 2.5L) in the USA 8 by 8 is widely believed to improve kidney health Three cross-sectional epidemiological studies USA - NHANES Total water intake Prevalence of CKD significantly higher among those with lowest (< 2 litres/day) versus highest (> 4.3 litres/day) Sontrop JM et al. Am J Nephrol 2013;37:434
28 Is there a right amount of fluid to drink if you have CKD? Drinking eight glasses of water each day (~ 2.5L) in the USA 8 by 8 is widely believed to improve kidney health Three cross-sectional epidemiological studies USA - NHANES Total water intake Prevalence of CKD significantly higher among those with lowest (< 2 litres/day) versus highest (> 4.3 litres/day) Sontrop JM et al. Am J Nephrol 2013;37:434 AUSTRALIA Nutrition questionnaires Highest quintile of fluid intake (3.2 L/day) - significantly lower risk of CKD Strippoli GF et al. Nephrology 2011;16:326.
29 Is there a right amount of fluid to drink if you have CKD? Drinking eight glasses of water each day (~ 2.5L) in the USA 8 by 8 is widely believed to improve kidney health Three cross-sectional epidemiological studies USA - NHANES Total water intake Prevalence of CKD significantly higher among those with lowest (< 2 litres/day) versus highest (> 4.3 litres/day) Sontrop JM et al. Am J Nephrol 2013;37:434 AUSTRALIA Nutrition questionnaires Highest quintile of fluid intake (3.2 L/day) - significantly lower risk of CKD Strippoli GF et al. Nephrology 2011;16:326. CANADA Urine volume Urine volume 3 L/d significantly less likely to have rapid GFR decline. compared to 1 to 1.9 L/d Clark WF et al. CJASN 2011; 6 :2634
30 Is there a right amount of fluid to drink if you have CKD? BUT One longitudinal study AUSTRALIA Prospective, population-based cohort study n = 3858 Median follow up 13 years Daily fluid intake not associated with all-cause or cardiovascular mortality. Rate of egfr reduction not associated with fluid intake Palmer SC et al. NDT 2014 Jan 6. [Epub ahead of print]
31 Interventions to reduce progression of CKD what is the evidence? Quality of Evidence GOOD MODERATE INSUFFICIENT Evidence of HARM BP control RAS blockade Uric acid lowering Alkali Physical exercise Dietary protein restriction Smoking cessation Salt restriction Anemia correction Statins Weight loss High fluid intake Bardoxolone
32 Interventions to reduce progression INTERVENTIONS WITH MODERATE EVIDENCE Widely-used interventions Often have other potential benefits - e.g. reducing CV risk But do they delay progression? Uric acid reduction Alkali therapy Physical exercise Dietary protein restriction Smoking cessation Dietary salt restriction
33 Interventions to reduce progression INTERVENTIONS WITH MODERATE EVIDENCE Widely-used interventions Often have other potential benefits - e.g. reducing CV risk But do they delay progression? Uric acid reduction Alkali therapy Physical exercise Dietary protein restriction Smoking cessation Dietary salt restriction
34 Interventions to reduce progression INTERVENTIONS WITH MODERATE EVIDENCE Uric acid reduction Rationale uric acid is proinflammatory and vasculotoxic allopurinol is antinflammatory and cardioprotective
35 Interventions to reduce progression INTERVENTIONS WITH MODERATE EVIDENCE Uric acid reduction Rationale uric acid is proinflammatory and vasculotoxic allopurinol is antinflammatory and cardioprotective But does reducing uric acid delay progression? Primary gout n = 59 Colchicine + Allopurinol 2 years Allopurinol delayed progression Gibson T et al. Ann Rheum Dis 1982; 41: 59
36 Effect of Uric Acid lowering therapy on renal outcomes Effect of allopurinol on change in GFR from baseline. adequately powered randomised trials are need. Bose B et al. NDT 2014; 29: 406
37 Interventions to reduce progression INTERVENTIONS WITH MODERATE EVIDENCE Widely-used interventions Often have other potential benefits - e.g. reducing CV risk But do they delay progression? Uric acid reduction Alkali therapy Physical exercise Dietary protein restriction Smoking cessation Dietary salt restriction
38 Interventions to reduce progression INTERVENTIONS WITH MODERATE EVIDENCE RATIONALE for ALKALI THERAPY
39 Interventions to reduce progression INTERVENTIONS WITH MODERATE EVIDENCE RATIONALE for ALKALI THERAPY
40 Interventions to reduce progression INTERVENTIONS WITH MODERATE EVIDENCE RATIONALE for ALKALI THERAPY
41 Interventions to reduce progression INTERVENTIONS WITH MODERATE EVIDENCE Author Country n Inclusion Intervention Outcome De Brito-Ashurst 2009 ALKALI THERAPY UK 134 CKD4 HCO mmol/l NaHCO 3 mean g/d Reduced ESRD Delayed egfr decline Phisitkul 2010 USA 59 egfr HCO 3 >22 mmol/l Na citrate equivalent to Delayed egfr decline 1 mmol/kg/d NaHCO 3 Goraya 2012 USA 76 CKD4 HCO 3 <22 mmol/l NaHCO 3 1 mmol/kg/d egfr decline = comparator (fruit & veg diet) Mahajan 2010 USA 120 CKD2 HCO 3 >24.5 mmol/l NaHCO mmol/kg/d Delayed egfr decline
42 Interventions to reduce progression INTERVENTIONS WITH MODERATE EVIDENCE ALKALI THERAPY - meta-analysis 4 long term studies follow up 1-5 yr, n = 295 INCREASED REDUCED NOT CHANGED Serum bicarbonate Fall in GFR Serum potassium Serum chloride Systolic BP Susantitaphong P et al. Am J Nephrol 2012; 35: 540
43 Interventions to reduce progression INTERVENTIONS WITH MODERATE EVIDENCE ALKALI THERAPY Current guidelines recommend sodium bicarbonate when serum HCO 3 <22 mmol/l
44 Interventions to reduce progression INTERVENTIONS WITH MODERATE EVIDENCE ALKALI THERAPY Current guidelines recommend sodium bicarbonate when serum HCO 3 <22 mmol/l 3 RCTs recruiting USA: CKD 3b-4, age > 18 yrs - normal and low serum HCO 3 USA: Diabetes CKD2-4, age > 18 yrs - normal serum HCO 3 UK : CKD4-5, age > 65yrs, low serum HCO 3
45 Interventions to reduce progression INTERVENTIONS WITH MODERATE EVIDENCE Widely-used interventions Often have other potential benefits - e.g. reducing CV risk But do they delay progression? Uric acid reduction Alkali therapy Physical exercise Dietary protein restriction Smoking cessation Dietary salt restriction
46 Low cost Low risk Available
47 Physical exercise and CKD progression Aerobic exercise in CKD Reduces systemic inflammation Improves BP control Improves exercise capacity Improves quality of life Resistance exercise in CKD Increases muscle mass Three RCTS of aerobic exercise in CKD have not shown alterations in rate of progression. but were not designed to test this
48 Physical exercise and CKD progression
49 Physical exercise and CKD progression Aerobic exercise in CKD Reduces systemic inflammation Improves BP control Improves exercise capacity Improves quality of life
50 Physical exercise and CKD progression Aerobic exercise in CKD Reduces systemic inflammation Improves BP control Improves exercise capacity Improves quality of life Resistance exercise in CKD Increases muscle mass
51 Physical exercise and CKD progression Community-based cohort study Greater physical activity exercise associated with lower rates of decline of kidney function Robinson-Cohen C et al. Arch Int Med 2009; 169:2016
52 Physical exercise and CKD progression Community-based cohort study Greater physical activity exercise associated with lower rates of decline of kidney function Robinson-Cohen C et al. Arch Int Med 2009; 169:2016 Longtitudinal cohort study n = 256 CKD stages 3 & 4 Validated questionnaire yrs follow up Robinson-Cohen C et al. CJASN 2014; 25: 390
53 Physical exercise and CKD progression Community-based cohort study Greater physical activity exercise associated with lower rates of decline of kidney function Robinson-Cohen C et al. Arch Int Med 2009; 169:2016 Longtitudinal cohort study n = 256 CKD stages 3 & 4 Validated questionnaire yrs follow up >150 min activity per week = slowest GFR decline Robinson-Cohen C et al. CJASN 2014; 25: 390
54 Physical exercise and CKD progression Community-based cohort study Greater physical activity exercise associated with lower rates of decline of kidney function Robinson-Cohen C et al. Arch Int Med 2009; 169:2016 Longtitudinal cohort study n = 256 CKD stages 3 & 4 Validated questionnaire yrs follow up >150 min activity per week = slowest GFR decline Each 60 min increment in exercise 0.5% slower GFR decline per yr Robinson-Cohen C et al. CJASN 2014; 25: 390
55 Physical exercise and CKD progression Community-based cohort study Greater physical activity exercise associated with lower rates of decline of kidney function Robinson-Cohen C et al. Arch Int Med 2009; 169:2016 Large RCTs with Longtitudinal cohort study n = 256 CKD stages 3 & 4 hard renal endpoints Validated questionnaire yrs follow up are now justified >150 min activity per week = slowest GFR decline Each 60 min increment in exercise 0.5% slower GFR decline per yr Robinson-Cohen C et al. CJASN 2014; 25: 390
56 Interventions to reduce progression INTERVENTIONS WITH MODERATE EVIDENCE Widely-used interventions Often have other potential benefits - e.g. reducing CV risk But do they delay progression? Uric acid reduction Alkali therapy Physical exercise Dietary protein restriction Smoking cessation Dietary salt restriction
57 Interventions to reduce progression of CKD what is the evidence? Quality of Evidence GOOD MODERATE INSUFFICIENT Evidence of HARM BP control RAS blockade Uric acid lowering Alkali Physical exercise Dietary protein restriction Smoking cessation Salt restriction Anemia correction Statins Weight loss High fluid intake Bardoxolone
58 Interventions to reduce progression INTERVENTIONS WITH GOOD EVIDENCE BLOOD PRESSURE CONTROL RAS BLOCKADE
59 BP TREATMENT RECOMMENDATIONS FOR CHRONIC KIDNEY DISEASE EVIDENCE Trials with hard renal endpoints Trials with surrogate renal endpoints Subgroup analysis of trials with a primary cardiovascular focus Observational association studies
60 BP TREATMENT RECOMMENDATIONS FOR CHRONIC KIDNEY DISEASE There are two RCTs with hard renal endpoints MDRD Long follow up 3 yr trial 10 yr total GFR GFR Usual BP < 140/90 Low BP < 125/75 ESRD reduced by low BP target only if up > 1g/d
61 BP TREATMENT RECOMMENDATIONS FOR CHRONIC KIDNEY DISEASE There are two RCTs with hard renal endpoints MDRD Long follow up 3 yr trial 10 yr total GFR GFR Usual BP < 140/90 Low BP < 125/75 ESRD reduced by low BP target only if up > 1g/d
62 BP TREATMENT RECOMMENDATIONS FOR CHRONIC KIDNEY DISEASE There are two RCTs with hard renal endpoints AASK Achieved Primary end point : no difference Low BP 128/78 Normal BP 141/85 Subgroup analysis, prolonged follow up: differences emerge
63 BP TREATMENT RECOMMENDATIONS FOR CHRONIC KIDNEY DISEASE There are two RCTs with hard renal endpoints AASK Achieved Primary end point : no difference Low BP 128/78 Normal BP 141/85 Subgroup analysis, prolonged follow up: differences emerge
64 BP TREATMENT RECOMMENDATIONS FOR CHRONIC KIDNEY DISEASE Proteinuria < 1g/24hr 130/80 Proteinuria > 1g/24hr 125/75 JNC7 European Task Force KDOQI etc.
65 BP TREATMENT RECOMMENDATIONS FOR DIABETIC KIDNEY DISEASE No RCTs with hard renal endpoints Post hoc analyses diabetes with overt nephropathy Cooperative Study Group 1999 Achieved SBP 130 = IDNT 2005 GFR loss only 2ml/min/yr RENAAL 2003 Every 10 mm Hg rise in systolic BP increased risk for ESRD or death by 6.7% SBP < 120 mm Hg all-cause mortality increased
66 BP TREATMENT RECOMMENDATIONS FOR DIABETIC KIDNEY DISEASE No RCTs with hard renal endpoints Post hoc analyses diabetes with overt nephropathy Cooperative Study Group 1999 Achieved SBP 130 = GFR loss only 2ml/min/yr These data led to guideline recommendations of SBP < 130 for overt diabetic nephropathy IDNT 2005 RENAAL 2003 Every 10 mm Hg rise in systolic BP increased risk for ESRD or death by 6.7% How achievable is this? Multiple drugs, multiple visits SBP < 120 mm Hg all-cause mortality increased
67 BP TREATMENT RECOMMENDATIONS FOR DIABETIC KIDNEY DISEASE No RCTs with hard renal endpoints Post hoc analyses diabetes with overt nephropathy Cooperative Study Group 1999 Achieved SBP 130 = GFR loss only 2ml/min/yr But what about the majority of diabetics who do not have overt diabetic nephropathy? IDNT 2005 RENAAL 2003 Every 10 mm Hg rise in systolic BP increased risk for ESRD or death by 6.7% We know that: Only 10% of diabetics have overt nephropathy YET 25% of diabetics age > 65yrs have egfr<60 SBP < 120 mm Hg all-cause mortality increased
68 BP TREATMENT RECOMMENDATIONS FOR DIABETIC KIDNEY DISEASE WITHOUT PROTEINURIA Rely on post hoc analysis of large (4000+) trials addressing cardiovascular endpoints These trials include: few > 70 yrs few with microalbuminuria even fewer with overt diabetic nephropathy
69 BP TREATMENT RECOMMENDATIONS FOR DIABETIC KIDNEY DISEASE WITHOUT PROTEINURIA Rely on post hoc analysis of large (4000+) trials addressing cardiovascular endpoints These trials include: few > 70 yrs few with microalbuminuria even fewer with overt diabetic nephropathy Target BP?... or achieved BP? 3 different meta-analyses. debate about methodology.
70 Interventions to reduce progression INTERVENTIONS WITH GOOD EVIDENCE BLOOD PRESSURE CONTROL RAS BLOCKADE
71 Interventions to reduce progression INTERVENTIONS WITH GOOD EVIDENCE RAS BLOCKADE OVERT DIABETIC NEPHROPATHY Cooperative Study Group, RENAAL, IDNT ACEi or ARB reduce double scr & ESRD Post hoc proteinuria is a legitimate intermediate outcome measure
72 Interventions to reduce progression INTERVENTIONS WITH GOOD EVIDENCE RAS BLOCKADE OVERT DIABETIC NEPHROPATHY Cooperative Study Group, RENAAL, IDNT ACEi or ARB reduce double scr & ESRD Post hoc proteinuria is a legitimate intermediate outcome measure NON-DIABETIC PROTEINURIC CKD REIN-2, AASK, Benazapril ACEi or ARB reduce double scr & ESRD More proteinuria = greater benefit Proteinuria <0.5 g/d - no benefit
73 Interventions to reduce progression INTERVENTIONS WITH GOOD EVIDENCE RAS BLOCKADE OVERT DIABETIC NEPHROPATHY ACEi or ARB? Cooperative Study Group, RENAAL, IDNT ACEi or ARB reduce double scr & ESRD Post hoc proteinuria is a legitimate intermediate outcome measure No difference in renal outcomes DETAIL Study ARB better tolerated? COST NON-DIABETIC PROTEINURIC CKD REIN-2, AASK, Benazapril ACEi or ARB reduce double scr & ESRD More proteinuria = greater benefit Proteinuria <0.5 g/d - no benefit
74 Interventions to reduce progression INTERVENTIONS WITH GOOD EVIDENCE RAS BLOCKADE NON-PROTEINURIC CKD Adults > 70yrs & egfr<60: only 5% have proteinuria >0.5g/d Rely on subanalyses of large CV trials 75% of the studies did not include >70yr
75 Interventions to reduce progression INTERVENTIONS WITH GOOD EVIDENCE RAS BLOCKADE NON-PROTEINURIC CKD Adults > 70yrs & egfr<60: only 5% have proteinuria >0.5g/d Rely on subanalyses of large CV trials 75% of the studies did not include >70yr - NO evidence that renal endpoints are improved by RAS blockade in non-proteinuric CKD
76 Interventions to reduce progression INTERVENTIONS WITH GOOD EVIDENCE COMBINATION RAS BLOCKADE
77 Interventions to reduce progression INTERVENTIONS WITH GOOD EVIDENCE COMBINATION RAS BLOCKADE in proteinuric CKD COOPERATE Study
78 Interventions to reduce progression INTERVENTIONS WITH GOOD EVIDENCE COMBINATION RAS BLOCKADE in proteinuric CKD COOPERATE Study
79 META-ANALYSIS OF COMBINATION ACEi & ARB IN PROTEINURIC IgA NEPHROPATHY 6 RCTs 109 patients follow up 2-12 months PROTEINURIA REDUCED No effect on: GFR BP Serum K Cheng J et al. Int J Clin Pract 2012; 66: 10
80 Interventions to reduce progression INTERVENTIONS WITH GOOD EVIDENCE COMBINATION RAS BLOCKADE NON-PROTEINURIC CKD & CKD with CV disease ONTARGET ALTITUDE
81 ONTARGET A cardiovascular secondary prevention study (n=25,620) Combination RAS Blockade Study population Worse renal outcomes in combination group Mean age 66yr 69% hypertension 37% DM 13% microalbuminuria 4% macroalbuminuria More hypotension More hyperkalaemia More doubling scr More dialysis for AKI
82 ALTITUDE High risk type 2 diabetes (n=8,561) Combination RAS Blockade using direct renin inhibitor Study population Worse renal outcomes in combination group Mean age 64.5yr 95% hypertension 100% DM 26% microalbuminuria 58% macroalbuminuria More hypotension More hyperkalaemia More AKI Renal outcome not different ESRD
83 Interventions to reduce progression INTERVENTIONS WITH GOOD EVIDENCE COMBINATION RAS BLOCKADE VA NEPHRON-D Type 2 DM > 18yr Stage 2-3 CKD Albuminuria > 0.3g/g Data collection finishing Sept 2014
84 BP TREATMENT RECOMMENDATIONS FOR CHRONIC KIDNEY DISEASE RAS BLOCKADE First line therapy for BP in proteinuric CKD Little or no benefit in non-proteinuric CKD except in diabetes where they delay progression through microalbumunuria to overt diabetic nephropathy Combination RAS blockade: safe and effective in young proteinurics. but not in older vasculopaths
85 Interventions to reduce progression INTERVENTIONS WITH GOOD EVIDENCE BLOOD PRESSURE CONTROL RAS BLOCKADE
86 CONSENSUS BP TARGETS Proteinuria <0.3g/d Proteinuria 0.3-1g/d Proteinuria > 1g/d Non-diabetic < 140/90 <130/80 <130/80 or <125/75 if young and heavy proteinuria Diabetic SBP< DBP < 80 <130/80 < 130/80 or <125/75 if young and heavy proteinuria
87 CONSENSUS BP TARGETS & PREFERRED FIRST LINE AGENTS Proteinuria <0.3g/d Proteinuria 0.3-1g/d Proteinuria > 1g/d Non-diabetic < 140/90 <130/80 130/80 or <125/75 if young and heavy proteinuria Agent None preferred ACEi or ARB ACEi and ARB Diabetic SBP< DBP < 80 <130/80 < 130/80 or <125/75 if young and heavy proteinuria Agent ACEi or ARB ACEi or ARB ACEi or ARB
88 CONSENSUS BP TARGETS & PREFERRED FIRST LINE AGENTS Proteinuria <0.3g/d Proteinuria 0.3-1g/d Proteinuria > 1g/d Non-diabetic < 140/90 <130/80 <125/75 Agent None preferred BUT - use clinical None common preferredsense ACEi or ARB In older people titrate carefully with close attention for adverse events Diabetic SBP< DBP < 80 <130/80 < 130/80 or <125/75 if young and heavy proteinuria Agent ACEi or ARB ACEi or ARB ACEi or ARB
89 Interventions to reduce progression of CKD what is the evidence? Quality of Evidence GOOD MODERATE INSUFFICIENT Evidence of HARM BP control RAS blockade Uric acid lowering Alkali Physical exercise Dietary protein restriction Smoking cessation Salt restriction Anemia correction Statins Weight loss High fluid intake Bardoxolone
SLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota
SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone
Optimal blood pressure targets in chronic kidney disease
Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management
Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
Management of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
Launch Meeting 3 rd April 2014, Lucas House, Birmingham
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Launch Meeting 3 rd April 2014, Lucas House, Birmingham Prof Sunil Bhandari
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline
Systolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
Chronic Kidney Disease Management for Primary Care Physicians. Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015
Chronic Kidney Disease Management for Primary Care Physicians Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015 Singapore Renal Registry 2012 Incidence of Patients on Dialysis by Mode of Dialysis
Effective Treatment Strategies to Delay the Progression of Renal Disease in CKD
Effective Treatment Strategies to Delay the Progression of Renal Disease in CKD Csaba P Kovesdy, MD FASN Memphis VA Medical Center, Memphis TN University of Tennessee, Memphis TN Vitamin D Metabolic acidosis
23-Jun-15. Albuminuria Renal and Cardiovascular Consequences A history of progress since ,490,000. Kidney Center, UMC Groningen
Kidney function (egfr in ml/min) Albuminuria (mg/hr) Incidentie ESRD (%) 3-Jun- Number of patients worldwide that receives kidney replacement therapy Albuminuria Renal and Cardiovascular Consequences A
Guest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
Uric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
Diabetic Kidney Disease in the Primary Care Clinic
Diabetic Kidney Disease in the Primary Care Clinic Jess Wheeler, DO Nephrology 2015 Outline: 1. CKD/DKD is a growing problem 2. Diagnosis of Chronic Kidney Disease (CKD) 3. Diagnosis of Diabetic Kidney
CKD and risk management : NICE guideline
CKD and risk management : NICE guideline 2008-2014 Shahed Ahmed Consultant Nephrologist shahed.ahmed@rlbuht.nhs.uk Key points : Changing parameters of CKD and NICE guidance CKD and age related change of
Kidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE
Predicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
Reducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
Tread Carefully Because you Tread on my Nephrons. Prescribing Hints in Renal Disease
Tread Carefully Because you Tread on my Nephrons Prescribing Hints in Renal Disease David WP Lappin,, MB PhD FRCPI Clinical Lecturer in Medicine and Consultant Nephrologist and General Physician, Merlin
Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
Concept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA
Concept and General Objectives of the Conference: Prognosis Matters Andrew S. Levey, MD Tufts Medical Center Boston, MA General Objectives Topics to discuss What are the key outcomes of CKD? What progress
The CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meetings 1 st and 2 nd September 2016 - London and Leeds Prof Sunil
Management of Early Kidney Disease: What to do Before Referring to the Nephrologist
Management of Early Kidney Disease: What to do Before Referring to the Nephrologist Andrew S. Narva, MD, NIDDK Saturday, February 18, 2017 8:45 a.m. 9:30 a.m. Although evidence-based guidelines for managing
Chronic Kidney Disease. Paul Cockwell Queen Elizabeth Hospital Birmingham
Chronic Kidney Disease Paul Cockwell Queen Elizabeth Hospital Birmingham Paradigms for chronic disease 1. Acute and chronic disease is closely linked 2. Stratify risk and tailor interventions around failure
RATIONALE. chapter 4 & 2012 KDIGO
http://www.kidney-international.org chapter 4 & 2012 KDIGO Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus Kidney International Supplements (2012) 2, 363 369; doi:10.1038/kisup.2012.54
Prevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
Diabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
QUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
KDIGO conference on high CV risk associated with CKD. The role of BP in CKD stage 1-4
KDIGO conference on high CV risk associated with CKD The role of BP in CKD stage 1-4 Johannes Mann, MD & Catherine Clase, MB BChir Friedrich Alexander University, Erlangen-Nuremberg Munich General Hospitals,
Effective Health Care Program
Comparative Effectiveness Review Number 37 Effective Health Care Program Chronic Kidney Disease Stages 1 3: Screening, Monitoring, and Treatment Executive Summary Objectives This systematic review evaluates
Chronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
BASELINE CHARACTERISTICS OF THE STUDY POPULATION
Study Summary DAILY ORAL SODIUM BICARBONATE PRESERVES GLOMERULAR FILTRATION RATE BY SLOWING ITS DECLINE IN EARLY HYPERTENSIVE NEPHROPATHY This was a 5-year, single-center, prospective, randomized, placebo-controlled,
Morbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
Outline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions
Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions Andrew S Narva, MD Na/onal Kidney Disease Educa/on Program U.S. Department of Health and Human Services National Institute of
The CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
Chronic Kidney Disease DR. SANJAY PANDEYA MD. FRCPC.
Chronic Kidney Disease DR. SANJAY PANDEYA MD. FRCPC. Objectives Review CKD and its implications for the family physician Review the relevance of CKD and ESRD, its complications and management issues in
Diabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
Hypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
CKDinform: A PCP s Guide to CKD Detection and Delaying Progression
CKDinform: A PCP s Guide to CKD Detection and Delaying Progression Learning Objectives Describe suitable screening tools, such as GFR and ACR, for proper utilization in clinical practice related to the
6/10/2014. Chronic Kidney Disease - General management and standard of care. Management of CKD according to stage (KDOQI 2002)
Chronic Kidney Disease - General management and standard of care Dr Nathalie Demoulin, Prof Michel Jadoul Cliniques universitaires Saint-Luc Université Catholique de Louvain What should and can be done
Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
Transforming Diabetes Care
Transforming Diabetes Care Diabetic Kidney Disease: Prevention, Detection and Treatment Alexis Chettiar, ACNP-BC, PhD(c) 1 Polling Question - 1 What is your role as a healthcare provider? a) Dietitian
Important aspects of acid-base disorders
Important aspects of acid-base disorders I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Division of Nephrology, Hypertension and Transplantation University of Florida College
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
Treating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
RENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2
Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic
OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016
Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
Stages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
Blood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
Hypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
CKD IN THE CLINIC. Session Content. Recommendations for commonly used medications in CKD. CKD screening and referral
CKD IN THE CLINIC Family Physician Refresher Course Lisa M. Antes, MD April 19, 2017 No disclosures Session Content 1. 2. Recommendations for commonly used medications in CKD Basic principles /patient
Faculty/Presenter Disclosure
CSI for CKD Unravelling the myths surrounding chronic kidney disease Practical Evidence for Informed Practice Oct 21 2016 Dr. Scott Klarenbach University of Alberta Slide 1: Option B (Presenter with NO
Management of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA
Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
Diabetic Kidney Disease: Update. GKA Master Class. Istanbul 2011
Diabetic Kidney Disease: Update GKA Master Class Istanbul 2011 DKD: Challenging dogmas Old Dogmas Type 1 and Type 2 DN have the same natural history Microalbuminuria is an early stage of DN Tight Glycemia
Chapter 7: Blood pressure management in elderly persons with CKD ND Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org chapter 7 & 2012 KDIGO Chapter 7: Blood pressure management in elderly persons with CKD ND Kidney International Supplements (2012) 2, 377 381; doi:10.1038/kisup.2012.57
Jared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
Combination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
Fructose, Uric Acid and Hypertension in Children and Adolescents
Fructose, Uric Acid and Hypertension in Children and Adolescents Daniel I. Feig, MD, PhD, MS Director, Division of Nephrology Department of Pediatrics University of Alabama, Birmingham Topics for Discussion
Clinical Pearls in Renal Medicine
Clinical Pearls in Renal Medicine Joel A. Gordon MD Professor of Medicine Nephrology Division Staff Physician Kidney Disease and Blood Pressure Clinic Disclosures None of my financial holdings will have
Managing patients with renal disease
Managing patients with renal disease Hiddo Lambers Heerspink, MD University Medical Centre Groningen, The Netherlands Asian Cardio Diabetes Forum April 23 24, 216 Kuala Lumpur, Malaysia Prevalent cases,
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
New Treatment Options for Diabetic Nephropathy patients. Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland
New Treatment Options for Diabetic Nephropathy patients Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland Diabetes and nephropathy Diabetic nephropathy is the most common
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
PRIMARY PHASE 2 ANALYSES FROM CARDINAL: A PHASE 2/3 STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME
PRIMARY PHASE 2 ANALYSES FROM CARDINAL: A PHASE 2/3 STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME 217 American Society of Nephrology Meeting Geoffrey A. Block 1, Pablo E. Pergola 2, Lesley
Outline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
Cardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
KDIGO Controversies Conference on Management of Patients with Diabetes and Chronic Kidney Disease
KDIGO Controversies Conference on Management of Patients with Diabetes and Chronic Kidney Disease February 5-8, 2015 Vancouver, Canada Kidney Disease: Improving Global Outcomes (KDIGO) is an international
Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
Dr. Mehmet Kanbay Department of Medicine Division of Nephrology Istanbul Medeniyet University School of Medicine Istanbul, Turkey.
The uric acid dilemma: causal risk factor for hypertension and CKD or mere bystander? Mehmet Kanbay, Istanbul, Turkey Chairs: Anton H. van den Meiracker, Rotterdam, The Netherlands Claudia R.C. Van Roeyen,
Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
Health Benefits of Lowering Sodium Intake in the US
Health Benefits of Lowering Sodium Intake in the US Lawrence J Appel, MD, MPH Professor of Medicine, Epidemiology and International Health (Human Nutrition) Director, Welch Center for Prevention, Epidemiology
Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
Review Advances in CKD 216 Published online: January 15, 216 Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Hillel Sternlicht George L. Bakris Department of Medicine, Section
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant
Arasu Gopinath, MD Nephrology Associates of Utah
Arasu Gopinath, MD Nephrology Associates of Utah Topics of interest PPI and CKD Diet soda consumption and risk of Incident ESRD Dietary red meat and kidney toxicity Chronic interstitial nephritis in agricultural
The CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
The CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
Hypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
New aspects of acid-base disorders
New aspects of acid-base disorders I. David Weiner, M.D. C. Craig and Audrae Tisher Chair in Nephrology Division of Nephrology, Hypertension and Transplantation University of Florida College of Medicine
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression Arasu Gopinath, MD Clinical Nephrologist, Medical Director, Jordan Landing Dialysis Center Objectives: Identify the most important risks
Office Management of Reduced GFR Practical advice for the management of CKD
Office Management of Reduced GFR Practical advice for the management of CKD CKD Online Education CME for Primary Care April 27, 2016 Monica Beaulieu, MD FRCPC MHA CHAIR PROVINCIAL KIDNEY CARE COMMITTEE
Update in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
Objectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
Too much sodium is bad for you. Too much sodium is bad for you 13/09/2014. Salt- intake around the world. Sodium the most famous electrolyte
Sodium the most famous electrolyte Too much sodium is bad for you High blood pressure Cardiovascular disease Kidney damage Cerebrovascular hemorrhage Gerjan Navis Dept Nephrology, UMCG Groningen The Netherlands
Disclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,